ED-Based Medications For Opioid Use Disorder Initiation-Establishing a Standard of Care
Date: 5/13/25 and 5/27/25
Noon – 1:00 p.m. Central time
Registration fee is $225 for BOTH webinars. You only need to register once to be automatically signed up for both webinars.
Audience:
Behavioral Health Directors, Directors of Emergency Department, Emergency Department Administrators, Case Managers, Peer Supports, Peer Navigators, Health Equity Directors, Directors of Addiction Medicine, and any other interested hospital staff.
This webinar series is hosted jointly by North Carolina Healthcare Association, North Carolina Healthcare Foundation and in cooperation with the Bridge Center.
Overview:
In this webinar series, Bridge Center staff will provide learners with a general overview and introduction to medications for opioid use disorder (MOUD), treatment best practices including ED-based buprenorphine, the efficacy and safety MOUD, and the mechanisms for associated navigation and harm reduction activities.
Learning Objectives:
-Synthesize the evidence supporting the efficacy and safety of buprenorphine as a medication for opioid use disorder.
-Identify the critical elements of an ED-based MOUD program.
-Summarize the importance of ED-based patient navigation services are critical to promoting ongoing recovery after ED-based MOUD initiation.
Speaker:
Arianna Campbell, DMSc, MPH, PA-C – Senior Director/M-Principal Investigator
Arianna is an Emergency and Addiction Medicine PA with more than 25 years of clinical experience. She works in Emergency and Addiction Medicine at the VA in Sacramento and serves as Senior Director and M- Principal Investigator for The Bridge Center at PHI, a program for which she is a co-founder. She is Director-at-Large for CAPA and is a CE committee member and Presidential Taskforce member for ASAM.
Josh Luftig, PA-C, Founder, Director of Harm Reduction Services
Josh has over 22 years of experience in Emergency Medicine. He is a co-founder of CA Bridge, and serves as the Director of Harm Reduction. Josh co-established one of the nation’s largest ED-based MAT initiation programs at Highland Hospital in Oakland, CA, and co-developed a novel high-dose rapid buprenorphine induction protocol which has been adopted statewide. He also created one of the first high-volume, low-threshold ED-based naloxone distribution programs, resulting in a 65-fold increase in the naloxone provisioning rate.
No Comments